A biomarker that can help predict the success of chemotherapy in ovarian cancer patients has been discovered by researchers.
The discovery, by cancer researcher Madhuri Koti of Queen’s University, could lead to better treatment options in the fight against ovarian cancer.
Biomarkers are an indicator of a biological state or condition.
"Recent successes in harnessing the immune system to combat cancer are evidence for the significant roles of a cancer patient's immune responses in fighting cancer," Koti explains. "Many of these successes are based on boosting anti-cancer immunity via different therapies. Such therapies would prove to be most effective when coupled with markers predicting a patient's eventual response to a specific therapy".
Koti conducted the study in retrospective cohorts of more than 200 ovarian cancer patients. The study utilized a combination of cutting-edge and more established detection technologies for identifying such markers.
A major impact of this discovery is that these novel markers, when used at the time of treatment initiation in the specific type of ovarian cancer patient, will help oncologists make decisions on additional treatment needed in these patients, thus increasing their potential for survival.
Ovarian cancer is responsible for approximately 152,000 deaths worldwide each year. It has the highest mortality rate of all gynaecological cancers.
For our BCC Research reports on cancer or biomarkers, visit the following links:
Therapeutics for 'Silent' Cancers (PHM169A)